Lv3
230 积分 2024-12-31 加入
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
1个月前
已完结
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
1个月前
已关闭
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
1个月前
已完结
Pediatric Versus Adult Chronic Rhinosinusitis
1个月前
已完结
Bispecific Antibodies for Glomerular Diseases
2个月前
已关闭
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives
2个月前
已完结
Condensed vs. Standard Step‐Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma
3个月前
已完结
Bispecific antibodies: a mechanistic review of the pipeline
3个月前
已完结
The present and future of bispecific antibodies for cancer therapy
3个月前
已完结
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
4个月前
已完结
皖公网安备34019202002308
